Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs
First subject dosed in Phase 1 trial of PYX-106, a fully human immunotherapy antibody candidate…
First subject dosed in Phase 1 trial of PYX-106, a fully human immunotherapy antibody candidate…
First subject dosed in Phase 1 trial of PYX-106, a fully human immunotherapy antibody candidate…
BERKELEY HEIGHTS, N.J., May 30, 2023 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical…
BERKELEY HEIGHTS, N.J., May 30, 2023 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical…
Results Add to Growing Body of Evidence that Inhibiting PP2A with LB–100 May Be a…
Results Add to Growing Body of Evidence that Inhibiting PP2A with LB–100 May Be a…
TAMPA, Fla. and MENLO PARK, Calif., May 30, 2023 (GLOBE NEWSWIRE) — Morphogenesis, Inc. (“Morphogenesis”),…
TAMPA, Fla. and MENLO PARK, Calif., May 30, 2023 (GLOBE NEWSWIRE) — Morphogenesis, Inc. (“Morphogenesis”),…
CORAL GABLES, Fla., May 30, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq:…
CORAL GABLES, Fla., May 30, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq:…
CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology…
CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology…
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company…
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company…
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage…
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage…
New data show continued durability of response over 14 months with humoral immune responses increasing…
New data show continued durability of response over 14 months with humoral immune responses increasing…
BRISBANE, Calif., May 30, 2023 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage…
BRISBANE, Calif., May 30, 2023 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage…